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2. List of abbreviations 
AC  Anterior Chamber 
ACAID Anterior Chamber-associated Immune Deviation  
AU  Anterior Uveitis 
BCVA  Best Corrected Visual Acuity 
BRB  Blood Retinal Barrier 
BM  Bone Marrow 
CRT  Central Retinal Thickness 
CME  Cystoid Macular Edema 
ETDRS  Early Treatment for Diabetic Retinopathy Study 
EXF  Extracellular Fluid 
HLA  Human Leukocyte Antigen 
IOL  Intraocular Lens 
IOP   Intraocular Pressure 
IGS  Irvine-Gass Syndrome 
ICF  Intracellular Fluid 
IVT  Intravitreal Therapy 
IUSG   International Uveitis Study Group 
KPs  Keratic Precipitates 
logMAR logarithm of Minimum Angel of Resolution  
ME  Macular Edema 
MTX  Methotrexate 
MV  Macular Volume 
NSAID Non-Steroidal Anti-Inflammatory Agents 
OCT  Optical Coherence Topography 
ON  Optic Nerve 
RPE  Retina Pigment Epithelium 
SD  Standard Deviation  
SUN  Standardization of Uveitis Nomenclature 
TNF-α  Tumor Necrosis Factor- α 
VA  Visual Acuity 
VEGF  Vascular Endothelial Growth Factor 
VKH   Vogt-Koyanagi-Harada 
VMTS  Vitreomacular Traction Syndrome 
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3. Introduction of uveitis 
3.1. Definition 
The term uveitis encompasses inflammation of all intraocular structures, not only uvea, ciliary 
body and iris, but also anterior chamber, vitreous, retina and retinal vessels, papilla as well as 
retinal pigment epithelium. Various etiologies cause uveitis like infections, autoimmunity and 
tumors. 1, 2 
3.2. Classification 
There are several ways to classify uveitis. An accurate classification is the first step to identify 
and diagnose any uveitic entity and it plays an important role to evaluate and determine the 
proper management and therapy of any uveitic case.  
The commonest classification of uveitic diseases was published in 1987 by the International 
Uveitis Study Group (IUSG), which basically differentiates according to the anatomical site 
with the most intense inflammation. The anatomical classification is the first step for 
identification of uveitis entity and treatment.  
The classification system is also supported from the Standardization of Uveitis Nomenclature 
(SUN). (Table 3.2.1 a, b) 
Table 3.2.1 a 
Anatomical classification according to SUN 3 
 Primary inflammatory site Uveitis types 
Anterior 
Uveitis 
Anterior chamber Iritis 
Iridocyclitis 
Anterior cyclitis 
Intermediate 
Uveitis 
Vitreous +/- pars plana Pars planitis 
Posterior cyclitis 
Hyalitis (Vitritis) 
Posterior 
Uveitis 
Retina and choroid Focal, multifocal, diffuse 
Choroiditits 
Chorioretinitis 
Retinochoroiditis 
Retinitis 
Neuroretintis 
Panuveitis 4 All anatomical structures (Anterior 
chamber, vitreous, retina, choroid) 
Endophthalmitis 
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Table 3.2.1 b 
Differential diagnosis for uveitis according to anatomical classification 5 
Acute anterior uveitis Chronic anterior uveitis 
Seronegative spondyloarthropathies 
Behçet’s syndrome 
Herpetic (HSV, VZV, CMV) 
Glaucomatocyclitic crisis (Posner-Schlossman-
syndrome) 
Post-streptococcal 
Tubulointerstitial nephritis and uveitis syndrome 
Juvenile idiopathic arthritis 
Sarcoidosis 
Fuchs uveitis (persistent rubella 
infection) 
Syphilis 
Tuberculosis 
Herpetic 
Intermediate uveitis Posterior uveitis Panuveitis 
Multiple sclerosis  
Idiopathic 
Sarcoidosis  
Lyme disease 
Toxoplasmosis 
Toxocariasis 
Sarcoidosis 
Syphilis 
Tuberculosis 
Viral (HSV, VZV, CMV) 
Birdshot choroidopathy 
Ocular histoplasmosis 
Multifocal choroiditis/panuveitis 
Retinal vasculitis 
Cerebral vasculitis 
VKH disease 
Behcet’s disease 
Sympathetic ophthalmia 
Sarcoidosis 
Toxoplasmosis 
Toxocariasis 
Syphilis 
Tuberculosis 
Endophthalmitis 
 
In 2005, SUN has presented an additional classification system according to the diagnostic 
terminology, outcome measures (VA outcome) 6 and grading schema of inflammation 
(anterior chamber cells and flares, vitreous haze). 7 
In 2008, the International Uveitis Study Group (IUSG) has presented a new classification 
system according to etiology. (Table 3.2.2) 
 
 
Table 3.2.2 
Classification system according to IUSG 
Infectious Viral, bacterial, parasitic, fungal 
Non infectious with positive or negative history of systemic associations 
Masquerade neoplastic, non-neoplastic 8 
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Different aspects can be used to classify uveitis type. (Table 3.2.3 a-c) 
Table 3.2.3 a 
Classification according to duration and course of uveitis 
Time of onset Sudden 
Insidious 
 
Duration Limited 
Persistent 
< 3 months duration 
> 3 months duration 
Course Acute 
Recurrent 
 
Chronic 
Sudden onset and limited duration 
Repeated episodes with inactive interval without treatment > 3 
months duration 
Persistent uveitis with relapse in < 3 months after discontinuing 
treatment 
 
 
Table 3.2.3 b 
Classification according to inflammatory type and clinical findings 
Type of inflammation Granulomatous  
Non granulomatous 
Lesion type Focal 
Multifocal 
Disseminated 
Diffuse 
Keratic precipitates type Focal 
Central or peripheral 
Disciform 
Arlt triangle 
Stellate or diffuse 
Other findings 9 Synechiae 
Fibrin 
Nodules 
 
 
Table 3.2.3 c 
Other classification type factors 
Laterality Unilateral or bilateral 
Age of onset infant, child, adolescent, young adult, elderly adult 
Demographics Sex, travel, race, occupation, residence location(s), immigration, other 
illnesses, hobbies, nutritional factors, stress and personality factors, pets 
Social history drug abuse, alcohol, smoking, sexual habits 
9 
 
Another etiopathological classification system divides uveitis in two main groups, 
granulomatous and non-granulomatous. (Table 3.2.4) This can differentiate the type of 
inflammation (involved cells) and the different clinical findings such as corneal endothelial 
keratic precipitates (KPs). KP have a different appearance in non-granulomatous (fine 
collection predominantly of granulocytes) than in granulomatous type (larger collection of 
macrophages and multinucleated cells with fatty appearance, mutton fat KP). This can be a 
diagnostic indicator and is helpful for the differential diagnosis. In granulomatous cases, 
typical iris and choroid changes such as iris nodules or choroidal and retinal granulomas may 
occur. 10 
 
 
Table 3.2.4 
Classification according type of inflammation  
Non granulomatous inflammation Granulomatous inflammation 
HLA-B27 syndromes 
Behcet’s disease 
Uveitis associated with multiple 
Sclerosis 
Juvenile idiopathic arthritis 
Syphilis 
Acute bacterial endophthalmitis 
Sarcoidosis 
Sympathetic ophthalmia 
Uveitis associated with multiple sclerosis 
Lens-induced uveitis 
Intraocular foreign body 
Vogt–Koyanagi–Harada syndrome 
Chronic or persistent infections like syphilis, 
tuberculosis, viral infection with HHV 1-5 or rubella 
and fungal infections 
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3.3. Etiology 
The identification of the etiology eye is most important for the correct management. Uveitis 
can be caused or associated with several etiological factors or diseases. Sometimes during the 
therapy of an uveitic eye, the exact etiology remains unknown but it is treated as a part of an 
etiologic category. 
The etiological classification 11 is the following: 
Infectious causes 
This group can be classified according to the etiological pathogen or according to 
transmission route and the primary infection locus. (Table 3.3.1) 
Table 3.3.1 
Infection etiology according to the pathogenicity 
Bacteria Treponema pallidum, Mycobacterium tuberculosis, Brucella, Mycobacterium 
leprae, Bartonella, Tropheryma whippelii 
Fungi Candida, Aspergillus, Fusarium, Cryptococcus, Coccidioides 
Protozoa Toxoplasma gondii, Toxocara canis, Taenia solium, Onchocerca volvulus 
Viruses Herpes simplex, Varicella zoster, Cytomegalovirus, Ebstein-barr virus, Human 
immunodeficiency virus, Measles and Rubella virus 
 
 
Non-infectious causes (Table 3.3.2) 
Table 3.3.2  
Non-infectious uveitis 12 
Autoimmune 
disease 
(associated 
with 
underlying 
disease) 
HLA-B27 associated diseases: ankylosing spondylitis, reactive arthritis, 
psoriatic arthritis, bowel disease (Crohn’s disease, ulcerative colitis) 
Psoriasis  
Juvenile idiopathic arthritis 
Multiple sclerosis (HLA-DR 15) 
Behcet’s disease (HLA-B5 / B51) 
Sarcoidosis 
Idiopathic Acute posterior multifocal placoid pigment epitheliopathy  
Multiple evanescent white dot syndrome  
Multifocal choroiditis (Punctate inner choroiditis) 
Serpiginous choroiditis 
Birdshot chorioretinopathy 
Acute zonal occult outer retinopathy 
Presumed Ocular Histoplasmosis Syndrome 
11 
 
Masquerade syndromes (neoplastic) causes 
Systemic hematological tumors, mainly malignant such as leukemia, lymphoma or even 
intraocular tumors such as retinoblastoma or melanoma of uvea may have uveitic 
manifestation. These cases can be also termed as masquerade syndromes 
Traumatic or iatrogenic causes 
Ocular injury (blunt or penetrating) may lead to uveitic presentation. This rarely can also 
happen after intraocular operation such as cataract, glaucoma or vitreoretinal operation. In 
rare cases medication may also cause an iatrogenic uveitis. 
 
3.4. Macular edema 
Macular edema (ME) is a common condition of central vision loss in the developed countries. 
It refers to an increase of retinal thickness at the macular area due to fluid accumulation. ME 
can also be defined as any pathological swelling of macula area.  
During the clinical examination there are several signs and symptoms that can associated with 
ME. (Table 3.4.1) 
 
Table 3.4.1 
Clinical manifestation in ME eyes 
Central vision distortion (blurry vision) with intact peripheral vision 
Color vision distortion 
Contrast sensitivity loss 
Metamorphopsia best tested with Amsler chart 13 
Absence of foveal depression 
Thickening fovea area 
Absence of foveal reflex can be seen in eyes with macula thickness over 300μm 14 
 
Macular edema and fluid accumulation can general be differentiated into intracellular and 
extracellular 15 (Table 3.4.2). Clinically can be evaluated with different parameters (Table 
3.4.3). There are several of these parameters that may be associated with different 
pathophysiological etiologies. 
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Table 3.4.2 
Classification of fluid accumulation in cellular level 
Intracellular (cytotoxic edema) Due to changes of cellular ionic distribution  
Extracellular Due to changes of blood retinal barrier 
 
 
Table 3.4.3 
Parameters of clinical evaluation in ME 
ME extent Areas with increased retinal thickness 
Central fovea status Involvement of fovea (central area 500 μm) 
ME distribution area Focal or diffuse ME 
Fluorescein leakage In case of BRP dysfunction or changes 
Vitreous status Presence or absence of vitreal traction 
Intra-retinal cyst It is sign of ischemia (defect of perifoveolar capillaries and / or 
capillary area closure) 
Localization of retinal 
thickness and cyst 
Inner or outer retina 
ME chronicity Duration from initial diagnosis and response to therapy 
 
Intracellular fluid (ICF) accumulation may be associated with several predisposing factors 
such as increased metabolic activity, Henle’s layer radial arrangement, absence of inner 
foveal layer, reduce or absence of foveal blood supply.16 This is mostly seen after ischemia, 
injury, toxic cell damage or inflammation.  
Extracellular fluid (ECF) accumulation is more common and clinically more relevant. It is 
primarily associated with blood retinal barrier (BRB) breakdown. The tissue volume increases 
with fluid in retinal extracellular space. Retinal edema progression is secondary to blood 
retinal barrier (BRB) damage and depends on hydrostatic pressure and osmotic pressure 
difference gradients. 17 
Macular edema can be classified according to location of accumulated fluid in relation to 
anatomical retinal layer. (Table 3.4.4)  
Table 3.4.4 
Classification of fluid accumulation in histopathological / retinal layer level 
Intraretinal Fluid in neurosensory retinal layers 
Subretinal Fluid under RPE with separation from neurosensory retina 
Combined Fluid in intra- and subretinal compartment 
13 
 
Cystoid macular edema (CME) is a subtype of ME with similar characteristics clinically, in 
OCT and angiography. This neurosensory retinal layer change has a characteristic 
pseudocystic configuration and can cause a secondary distortion of the photoreceptor 
architecture.18 This type of edema is termed as cystoids because of its appearance. 
Anatomically it is not a true cyst because it lacks an epithelial coating. 
CME must be differentiated from subretinal edema and serous retinopathy. In serous 
retinopathy or serous retinal detachment there is a subretinal fluid accumulation which forces 
the neurosensory retina to separate from retinal pigment epithelium (RPE). It is categorized as 
atypical form of ME. 19 There are several conditions that present with this kind of macular 
edema: central serous chorioretinopathy (CSCR), retinal detachment and choroidal 
neovascular membrane belong to this group.20 
The mechanism of intraretinal fluid accumulation is associated with inner and outer blood 
retinal barriers dysfunction leading to an abnormal permeability and fluid leakage from the 
perifoveal retinal capillaries. The inner blood retinal barrier constitutes of tight junction 
between retinal vessels (which pass through inner retina) and endothelial cells. Some 
inflammatory mediators (prostaglandins, protein kinase C, vascular endothelial growth fact, 
nitric ocide, leukotriennes, or other cytokines) may cause a dysfunctional barrier. 21 The outer 
blood retinal barrier is localized between adjacent RPE cells and is supported by tight 
junctions.  
Normally, there is equilibrium between the capillary filtration rate and rate of fluid removal 
from extracellular retina. Under physiological conditions RPE removes fluid from the retina. 
In case of any functional failure or any balance disruption, extracellular fluid accumulates 
within retinal layer in cystic form.22 The outer plexiform and the inner nuclear layers are the 
main retinal layers where fluid accumulates. The outer plexiform layer is the initial layer of 
fluid accumulation due to anatomical position between retina and choroid where chorioretinal 
watershed area is present. Macula is more susceptible for fluid accumulation because of 
avascular zone, scarcity of Muller cells and vertical orientation of intraretinal fibers.23 Initially 
the fluid accumulates in intracellular space of Muller cells, which may then rupture and cause 
extracellular accumulation. 24,  25 (Figure 3.4.2) 
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Figure 3.4.2 
Inner and outer blood retinal barrier and associated locations26 
 
 
Several risk factors can play a role to a disruption of homeostatic mechanism of eye. (Table 
3.4.5) Any change between osmotic or hydrostatic force and retinal or choroidal vasculature 
can increase capillary permeability. 27, 28 Vitreous, retina, retinal pigment epithelium (RPE), 
choroid and vasculature play an important role in pathogenesis of ME.  
Table 3.4.5 
Retinal edema formation factors 29 
Blood retinal barrier permeability 
Capillary hydrostatic pressure 
Tissue hydrostatic pressure 
Tissue osmotic pressure 
Plasma osmotic pressure 
 
CME induced by inflammatory process is the most common complication in uveitic eyes, 
independent from etiology or anatomical location of inflammation (but mostly posterior 
uveitis). This can lead to significant VA reduction. 30, 31 It is due to retinal vessels damage 
following release of inflammatory mediators like interferon-γ, interleukin-2 / -10, tumor 
necrosis factor-α, VEGF. This process compromises the BRB leading to macular swelling.32,33 
There are several conditions and risk factors associated with fluid leakage and secondary ME 
formation.34 The etiological classification of ME is categorized according to patho-
mechanism of retinal dysfunction. (Table 3.4.6) 
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Table 3.4.6 
Cystoid macular edema associated diagnoses 
Vascular 
 
 
 
 
 
 
 
Retinal Diabetic retinopathy 
Retinal vein occlusion (branch or central) 
Retinal artery macroanuerysm 35 
Radiation retinopathy 
Juxtafoveal retinal telangiectasis 
Coats’disease 
Retinopathy of prematurity 
Ocular ischemic syndrome 
Choroidal Choroidal neovascularization (CNV) 
Hypertensive retinopathy 36 
Postoperative Irvine-Gass syndrome 
Penetrating keratoplasty 
Scleral buckle 
Laser treatment [Argon or YAG (Yttrium-Aluminum-Garnet)] 
Cryotherapy 
Inflammatory Uveitis and Neuroretinitis (Table 3.2.1b, 3.2.2 and 3.3.2) 
Medications Table (3.4.8) 
Retinal dystrophies Retinitis pigmentosa 37,  38 
Autosomal dominant cystoids macular edema 
Gyrateatrophy 
Goldman Favre (enhanced S-cone syndrome) 
Juvenile X-linked retinoschisis 
Tractional Epiretinal membrane (Macular pucker) 
Vitreomacular traction syndrome 
Vitreoretinal traction associated with myopia 
Macular hole 
Neoplastic (Tumor) 
 
 
Retinal Hemangiomas 
Choroidal Melanoma 
Hemangioma 
Osteoma 
Anatomical 
abnormalities 
 
Optic nerve 
 
Optic pit maculopathy 39 
Opticdisc coloboma 
Morning glory disc anomaly 
Retina Retinal detachment 
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Iatrogenic (postsurgical) or post traumatic 
Pars-plana vitrectomy, glaucoma or cataract operation, penetrating keratoplasty and even laser 
procedures (such as capsulotomy), can cause changes in the retinal blood flow and produce an 
inflammatory reaction.40 Irvine-Gass belongs to post-surgical inflammatory reaction after a 
cataract surgery, this occur in 20% of cataract operations or even more depending on duration 
of surgery and intra-operative complication. It usually manifests 6 to 10 weeks after surgery 
and resolves spontaneously in 95% of cases within 6 months and is the most common cause 
of VA reduction after a cataract surgery. 41, 42, 43, 44. Uveitis45, diabetic retinopathy46, intra-
operative vitreous loss 47 and intracapsular versus extracapsular surgery 48 are risk factor for 
Irvine-Gass ME formation 
The IGS patho-mechanism is not fully understood, inflammatory intraocular mediators 
(histamine, prostaglandins, leukotrienes) play an important role in increased vessel 
permeability.  
Another common condition for secondary ME is capsulotomy or panretinal photocoagulation. 
The associated mechanism is due to inflammatory mediator releasement or macular blood 
flow is increased and lead to transudation. 49 Capsulotomy related ME has a low incidence < 
3% but may be increased if performed in early period after the cataract surgery.  
Ocular immune privilege refers to several mechanisms that associated with regulation of 
ocular inflammation. Integrity of BRB is strongly associated with inflammatory process. The 
anterior chamber-associated immune deviation (ACAID) is strong enough to avoid any 
disruption of ocular immune privilege. An uni- or bilateral retinal laser therapy can cause a 
disruption of ACAID after changing the immune homeostasis and regulation system of both 
treated and non-treated eye. 50 
 
Medication 
Several drugs can induce ME. (Table 3.4.8) The most common are the prostaglandin analogs 
which can lead to vascular instability and disruption of capillaries junctions due to pro 
inflammatory effects.51 Other reports referred to epinephrine eye drops.52 Nicotinic acid and 
Niacinmay can also induce ME with a daily dose over 1,5g. 53 
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Table 3.4.8 
Medication associated with ME 
Benazalkonium chloride Carmustine Docetaxel 
Epinephrine Fingolimod Glitazones 
Niacin Paclitaxel Timolol 
Prostaglandin analoges Tamoxifen  
 
 
Intraocular neoplasms (tumors) 
Any type (malignant or benign) tumor may associate with ME creation. The most common 
tumors are choroidal or retinal capillary haemangioma, choroidal melanomas and 
vasoproliferative tumors. ME is associated with RPE and/ or blood retinal barrier dysfunction 
due to choroidal mass compression effect.54 
 
Tractional maculopathy  
Macular pucker, vitreomacular traction syndrome (VMTS) and myopic macular schisis 
belong to this group. These conditions have mechanical tractional component that cause an 
intraretinal fluid accumulation. Tractional forces cause stress at the retinal area of Muller cells 
and contribute to release of inflammatory factors (vascular endothelial growth factor, basic 
fibroblastic growth factor, platelet derived growth factor). This can produce a disruption of 
blood retinal barrier with secondary separation of retinal layer and retinal pigment epithelium, 
Muller cells lyses, fluid leakage and finally edema. 55, 56, 57, 58 Epiretinal membrane is due to 
cell proliferation with an avascular fibrous membrane formation. Tractional forces can cause 
secondary ME that do not response to local therapy. In VMTS case there is an anterior 
vitreous detachment that attach the macular area and tractional forces of attached vitreous can 
cause ME.59 
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3.5. Uveitic complications 
Uveitis is associated with intraocular complications such as cystoid macular edema60, cataract 
formation 61 (inflammatory or steroid induced 62) and secondary glaucoma 63 (inflammatory or 
steroid induced 64). All of these complications may influence the final visual prognosis and 
may play an important role for management decision.  
A conservative or surgical treatment may be indicated to treat intraocular uveitic complication 
and visual improvement secondarily. In case of early cataract formation, a cataract operation65 
with or without implantation of intraocular lens is the main treatment indication. In glaucoma 
cases, a primary conservative therapy with local or systemic medication may initial manage 
this condition and in severe or uncontrolled cases a laser or surgical treatment may be 
indicated. Most of the cases with CME respond well to topical or systemic steroids. 66  
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3.6. Treatment strategies of inflammatory macular edema 
Uveitic macular edema occur during active inflammation as well as in quiescent eyes. In order 
to treat ME inflammation has to be controlled as the first step. This includes the use of 
steroids, immunosuppressive agents as well as biologicals. In quiescent eyes with ME or in 
eyes in which ME persists even if inflammation is controlled, symptomatic treatment must be 
initiated. Different medications (Table 3.6.1) and routes of administration are available.67 
 
Table 3.6.1 
CME treatment options 
Steroid therapy (local, topical, systemic or combined) 
Non- steroidal anti-inflammatory drugs (local, topical, systemic or combined) 
Carbonic anhydrase inhibitors (systemic) 
Anti-vascular endothelial growth factor drug (intravitreal) 
Steroid sparing immunosuppressive agents (intravitreal or systemic) 
Macular grid laser 68 
Vitrectomy 69 
 
 
The route of administration may vary. The available routes for each substance are given in 
Table 3.6.2. 
Table 3.6.2 
Classification of therapy according to administration route 
Local Eye drops, ointments  
Topical Peri-ocular (retro- or para-bulbar), sub-conjunctival or intra-ocular injection 
Systemic Oral, intra-macular, intra-venous 
 
Steroids 
Steroid drugs are the most effective agents that can treat an inflammation process and 
subsequently the cystoid macular edema. The most potent agent is corticosteroid which has a 
broad effect in immune system, it targets to neutrophil transmigration and play a role to 
reduction of cytokine production. It has a primary anti-inflammatory action by prostaglandins 
and leukotrienes synthesis inhibition. In addition, the tight junctions of vascular endothelial 
cells are stabilized and thus leads to vessel sealing. 66 
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Local steroids (eye drops) 
Local steroids are mostly used in cases of anterior uveitis to control inflammation. Due to 
poor penetration of topically applied steroids to the posterior pole, a topical steroid therapy 
has no to mild effect on treatment of cystoid macular edema thus additional topical or 
systemic agents may be needed to treat the macular edema.70 
Periocular steroids 
Periocular administration allows for a better therapeutic concentration than local steroid 
therapy and it has a longer effect to because it acts as depot and penetration through the sclera 
is sufficient. The most common preparations are triamcinolone acetonide or 
methylprednisolone acetate. The periocular therapy is mainly indicated in unilateral or 
asymmetrical cases of intermediate or posterior uveitis, macular edema or in severe and 
resistance anterior uveitis. In case of bilateral posterior uveitis, a periocular therapy is 
considered as supplement to systemic therapy or if a systemic steroid therapy is 
contraindicated. Other possible indication is in patients with poor compliance with topical or 
systemic drugs. Sometimes a periocular steroid injection is used intra-operative to reduce 
post-operative inflammation and / or macula edema. 
Secondary cataract formation70, 71, 72, 73, globe penetration, elevation of IOP, refractory change 
from depot-mass effect, ptosis, subdermal fat atrophy, extraocular muscle paresis, optic nerve 
injury, retinal and choroidal vascular occlusion, cutaneous hypopigmentation are possible 
complication of a periocular steroid injection. 
The periocular injection is made under local anesthetic like tetracaine or scandicaine. There 
are several possible anatomical regions of the injection, sub-conjunctival, peri- or retrobulbar 
anatomical region. 74 
Topical (intraocular or intravitreal) steroids 75 
Triamcinolone acetonide is a short acting steroid option in case of posterior uveitis and 
macula edema recalcitrant to other therapies. It has an effect of 3 months when is injected 
intravitreally in comparison to periocular injection that has an effect of 4 weeks. It has rapid 
macula edema response and it is more potent than other periocular triamcinolone injections. It 
can be used intra-operatively as prophylaxis in patient with risk of an inflammation and / or 
post-operative macula edema. The possible complications are the same as in any intrevitreal 
injection such as IOP elevation76, cataract formation, endophthalmitis (sterile or infectious), 
hemorrhage and retinal detachment. 77, 78 
21 
 
 
Slow-release implants such as Ozurdex® 79 (0.7mg Dexamethasone), Iluvien® 80, 81 (0.19mg 
fluocinolone acetonide) are useful in cases of posterior uveitis that have low response or are 
intolerant to other treatments. The implants are injected intravitreally via pars plana and have 
a slow release reservoir function for 3-4 months (Ozurdex®) to 2-3 years (Iluvien®). This can 
reduce the use of long term systemic therapy. The efficacy of intravitreal Dexamethasone 
implant (Ozurdex®) is five time more potent than topical triamcinolone acetonide. 82 
Table 3.6.3 shows the possible ocular side effects after use of local, peri- or intraocular 
steroids. These side effects are depending on the duration of administration and the dose.  
 Table 3.6.3 
Ocular side effects after local, peri- or intraocular steroid therapy 83 
Cataracts 
Glaucoma 
Central serous retinopathy 
Delayed wound healing and infection risk 
Reactivation of herpes virus  
 
Systemic steroids 
Systemic steroids can be given orally or intravenously. They are indicated in intermediate and 
posterior uveitis. They are preferred in bilateral uveitic eyes with or without macular edema. 
Some studies have shown that systemic steroids induce resolution of macular edema faster 
than periocular steroids. 84 
Steroid therapy sometime is avoided as primary therapy in patient with high risk of adverse 
effects. 85Steroid must be used with caution in diabetic patients, patient with peptic ulcers, 
osteoporosis, active systemic infections and psychosis on past steroid exposure. 
Steroids are mostly used in acute conditions. Steroid sparing drugs may be added for chronic 
inflammation. 86 
Steroid treatment is started with a high dose and then to tapered slowly according to control of 
inflammation. Prednisolone is the most common preparation at an initial dose of 1-
2mg/kg/day in single morning dose. Regular clinical follow ups are required during weekly 
dose tapering. 
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The table 3.6.4 shows dose and administration route of common steroids.  
Table 3.6.4 
Administration route and doses of common used  
steroid agents  
Duration of anti -
inflammatory effect 
Triamcinolone acetonide Intravitreal 2–4 mg 1-3 months 
Periocular or 
retrobulbar 
40mg 4-6 weeks 
Dexamethasone implant 
(Ozurdex®) 
Intravitreal 0.7mg 3-5 months 
Fluocinolone acetonide implant 
(Iluvien®) 
Intravitreal 0.19 mg 2-3 years 
Prednisone Oral 1–2 
mg/kg/day 
1-2 days 
Methylprednisolone Intravenous 1g over 1-2 h 1-2 days 
 
Systemic steroid therapies cause adverse effects during administration. The side effects (Table 
3.6.5) mainly depend on the dose and the duration of administration. 
Table 3.6.5 
Side effect of steroid therapy87 
Fluids, electrolytes Musculoskeletal 
Sodium retention, potassium loss 
Fluid retention 
Hypokalemic alkalosis 
Hyperosmolar coma 
Muscle weakness 
Steroid induced myopathy 
Osteoporosis 
Femoral and humeral heads aseptic necrosis 
Tendon rupture 
Endocine Neurologic Gastrointestinal 
Menstrual irregularities 
Cushingoid state 
Growth suppression in children 
Hirsutism 
Adrenocortical pituitary axis suppression 
Diabetes 
Convulsions 
Headaches 
Hyperexcitability 
Moodiness 
Psychosis 
Mental changes 
Nausea 
Dyspepsia 
Increased appetite 
Peptic ulcer 
Intestine perforation 
Pancreatitis 
Dermatologic Other Ophthalmologic 
Poor wound healing 
Easy bruisability 
Increased sweating 
Weight gain 
Thrombo-embolism 
Infection reactivation 
Table 3.6.3 
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Prostaglandin inhibitors and non-steroid anti- inflammatory drugs (NSAID) (topical 
and systemic) 
Prostaglandin inhibitors can be used in some ocular inflammatory conditions. In some cases 
NSAID can reduces the severity and the recurrences of uveitis (mostly AU) when 
administrated in combination with steroids. NSAIDs are not used as first line therapy in 
uveitic patient (with or without macular edema) because of low effectivity as single agent in 
intraocular inflammation conditions. 88   
The most commonly used agent is diclofenac either as local or systemic agent. It is commonly 
used after capsulotomy or cataract operation to reduce the risk of any inflammatory response 
and secondary macula edema (Irvine-Gass-syndrome). 89, 90, 91 
NAISDs are anti-inflammatory agents that inhibit pro- inflammatory prostaglandins, 
thromboxane and cyclo-oxygenase production. 92, 93 Some studies have showed that 
Bromfenac and Nepafenac also have a therapeutic value for the treatment of macular edema. 
94, 95, 96 
Carbonic anhydrase inhibitors (Acetazolamide) and Somatostatin analogues 
Acetazolamide is a carbonic anhydrase inhibitor. The inhibition of carbonic anhydrase 
primary reduces aqueous humor production and also facilitates net-transport of water from the 
retina through the retinal pigment epithelium (RPE) into the choroid. Several studies have 
showed the effectiveness of acetazolamide as treatment for cystoid macular edema. 97, 98, 99 
Other studies have shown that somatostatin analogues such as Octreotide may reduce 
inflammatory macular edema in uveitic eyes by restoration of inner blood retinal barrier.100, 101 
Vascular endothelial growth factor inhibitors (intravitreal) 
Vascular endothelial growth factor is upregulated in inflammation and has a pro-inflammatory 
effect. It plays an important role in angiogenesis and retinal vascular permeability. 102103104 
These effects cause macular edema. Intravitreal injections of anti-vascular endothelial growth 
factor (anti-VEGF) such as ranibizumab, aflibercept and bevacizumab suppress macular 
edema. The effect of VEGF-inhibitors in inflammatory macular edema105, 106, 107, 108 are much 
less potent and therefore only second or third line therapy in the treatment of uveitic macular 
edema. In some cases secondary retinal vascularization develops during an uveitic 
inflammatory process109, in those cases an anti-VEGF intravitreal injection plays an primary 
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or additional role to treat the macular edema as well as the neovascularization. The source of 
VEGF in inflammation seems to be T-lymphocytes. 110 
Steroid sparing immunosuppressive or antimicrobial / antiviral agents 
Steroid sparing immunosuppressive drugs such as antimetabolites and biologicals are mostly 
used in cases of severe uveitic, bilateral involvement, non-infectious etiologies in patient with 
inadequate response to steroid therapy. It is also indicated in patient with systemic steroid 
intolerance, side effect111, 112 or in chronic disease that a prolonged or high daily dose of 
steroid is needed. The main administration route is systemic and in some cases also topical. 113 
Immunosuppressive114, 115, 116, 117 or anti-microbial or anti-viral therapies have no direct effect 
on cystoid macular edema but help secondarily by reducing inflammation. The most common 
immunosuppressive agents are summarized in table 5.5.7. 
Immunosuppressive agents are generally given for 2-3 years after induction of uveitis 
remission and then tapered. Some patients may require a prolong therapy to control active 
disease. 
Table 3.5.7 
Commonest steroid sparing immunosuppressive agents 
Antimetaboloites Azathioprine 
Methotrexate (MTX)118 
Mycophenolat emofetil 
Calcineurin inhibitors Ciclosporin 
Tacrolimus 
Biological blockers Interleukin receptor antagonists 
Tumor necrosis factor-α antagonists 
 
Macular grid laser coagulation and pars plana vitrectomy 
The effect of macular grid laser coagulation and pars plana vitrectomy have been studied for 
several years and have shown some effect on macular edema reduction. Both methods are not 
primarily indicated. 119, 120, 121 
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4. Goal of the study 
The aim of this study is to evaluate the clinical outcomes of 4 parameters (Visual acuity, 
central macular thickness, macular volume and intraocular pressure) after repeated intravitreal 
injection of 0.7 mg Dexamethasone implant (Ozurdex®) in defined follow up intervals.  This 
retrospective analysis includes only eyes with cystoids macular edema with non-infectious 
uveitis. 
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5. Material and methods 
5.1. Visual acuity (VA) 
The visual acuity (VA) level in uveitic eyes depends on several factors. Any pathological 
change that can decrease the transparency of the cornea, anterior chamber, lens and vitreous 
can reduce the VA. Any retinal clinical change such as macular edema, infiltration, scaring or 
necrosis can lead to a significant VA disturbance. In addition, the optic nerve pathology can 
also play an important role to VA level. Any VA disturbance should be evaluated to identify 
cause and appropriate treatment. 122, 123 
Testing VA is also an important tool to assess functional changes and one of the most 
important features for indication to therapy and follow ups.  
Distance and near vision should be tested with the best correction. Distance VA is mostly 
used as primary test but near VA sometime may improve earlier than the distance VA such in 
patient with chronic macular edema. 124, 125 
The VA is the ability of the eye to perceive and resolve an object and its details. The 
minimum angle of resolution (MAR) (Figure 5.1.1) is the angle between two objects in order 
to be resolved correctly on the retina. The minimum angle of resolution also depends on 
brightness and contrast of presented test objects. These parameters are standardized according 
to DIN-norms (58220).126 
Decimal visual acuity is calculated as the reciprocal of the minimal angle of resolution, which 
is the smallest recognized gap in the Landolt ring given in arcminute.  
1 
Decimal VA =–––––––––––––––––––––––––––––––––––––––––––––––––––––  
  smallest recognized gap in the Landolt ring given in arcminute 
It is possible to calculate the Log(MAR) from the decimal VA using the following formula:  
Log(MAR) = – Log (decimal VA) 
The advantage of Log(MAR) is that it is an logarithmic scale, which reflects the psychometric 
perception of vision. For instance: an doubling in visual acuity indicates a halving of the 
minimum angle of resolution. On a decimal scale this could be an increase of visual acuity 
from 0.1 to 0.2 or from 0.5 to 1.0 resulting in different numeric differences. On the 
logarithmic Log(MAR) scale this would be expressed as an increase by –0.3 independent of 
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the initial visual acuity. In the above example the Log(MAR) would increase from 1.0 to 0.7 
or from 0.3 to 0.0. Unfortunately the Log(MAR) scale is an inverted scale due to the minus in 
the formula, indicating better visual acuity by lower digits. The other major advantage of 
Log(MAR) scale is that is allows to mathematically  calculate average or changes in VA. Due 
to the logarithmic psychometric perception this would not be allowed on the decimal scale. 
(Table 5.1.1)  
Figure 5.1.1 
MAR (Minimum Angle of Resolution) 127 
 
 
Table 5.1.1 
Visual Acuity Scales 128 
Decimal LogMAR 
0.01 2.00 
0.025 1.60 
0.05 1.30 
0.10 1.00 
0.125 0.90 
0.16 0.80 
0.20 0.70 
0.25 0.60 
0.32 0.50 
0.4 0.40 
0.5 0.30 
0.63 0.20 
0.80 0.10 
1.00 0.00 
1.25 -0.10 
1.60 -0.20 
2.0 -0.30 
2.5 -0.40 
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In this study the visual acuity has been tested in predefined intervals. The best corrected 
visual acuity has been taken according to decimal VA method (DIN-norms: 58220). The 
values have been later converted to log MAR for the further statistical analysis.  
5.2. Intraocular pressure (IOP) measurement 
Intraocular pressure (IOP) is the pressure of the fluid inside the eye. It is a main diagnostic 
indicator to identify any type of glaucoma and the glaucoma therapy is based on IOP 
regulation. The normal IOP values are range from 8-21mmHg, with a normal average of 16 
+/- 2.5mmHg. Several factors can influence the IOP, such as age, race, genetics, obesity, 
blood pressure, exercise, Valsalva, posture, time of day, drugs, hormones, eye lid closure and 
any refractive error. 129 
There are several methods to measure the intraocular pressure. The gold standard method is 
the Goldmann applanation tonometry (Table 5.2.1). 
Table 5.2.1 
Steps of Goldmann applanation tonometry 130 
I Installation of local anesthetic eye drops with fluorescein dye 
II Set the blue filter of slit beam and shine onto the tonometer head with bright light. This 
show the fluorescein rings 
III Tonometer head should have perpendicular position to the eye and then move it forward 
until prism attach gently the central cornea 
IV Calibrate dial on the tonometer until the two margins of fluorescein semi rings meet each 
other in horizontally S shape and then note the reading on the dial 
Applanation tonometry rings with 
Goldmann prism 
Applanation tonometry 
  
All measurements of the intraocular pressure in our study are based on the Goldmann 
applanation method. 
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5.3. Ocular coherence tomography (OCT) 
OCT allows for measurement of vitreal, retinal and choroidal thickness in a non-invasive procedure 
(Table 5.3.1). It uses an interferometric method. This non-contact method can create a tomographic 
image of all retinal layers and can examine retinal areas with a sectional resolution of 10-15 
microns.131 It is a similar technique as the ultrasound, except that the image is created by reflection and 
backscattering of a laser beam. Any reflective property change between the tissues can be determined 
with this technique which is based on time domain or spectral domain protocols (Table 5.3.2). 132, 133 
Table 5.3.1 
OCT Functions 134 
Measures retinal thickness 
Measures retinal nerve fiber layer (RNFL) 
Measures retinal volume 
Creates retinal map 
Isolates and creates maps of internal limiting membrane and retinal pigment epithelium  
Measures optic disk parameters 
Displays 3-dimensional views 
Provides C-scan (en face) analyses, creating a section plane horizontally in tissue 
Offers RPE fit function 
 
Table 5.3.2 
Spectral domain OCT protocols 135, 136 
Resolution of 3 micrometer 
OCT images continuously in a 6mm area 
20.000-40.000 scans per second 
2 as well as 3 dimensional images 
 
It is the standard method in many retinal diseases (Table 5.3.3) such as macular edema (including the 
anatomical location of edema), macular pucker, macular hole, epiretinal gliosis, vitreo-macular 
traction, macular degeneration, neurosensory retinal or retinal pigment epithelium pathologies or 
detachments. OCT has the capability to monitor and compare any progression of the macular disease 
(macular thickness, retinal volume) as in cases of macular edema therefore it is an important tool to 
evaluate the efficacy of treatment and further management (Table 4). 137, 138 OCT has a limitation in 
eyes with a media opacity such vitreous hemorrhage, corneal scars or mature cataract. The quality of 
the OCT imaging depends on machine operator, patient cooperation, media clarity and type of OCT 
machine. 
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Table 5.3.3 
Anatomical OCT interpretation and associated diseases 139 
Preretinal Intraretinal Subretinal 
Posterior vitreous detachment 
Vitreomacular traction 
Epiretinal membrane 
Pseudo- lamellar- or macular hole 
Macula edema 
IGS 
Retinal exudates 
RPE detachment 
RPE tear 
Choroid 
CNV 
 
The anatomical regions of macula area are listed in Table 5.3.4 and figure 5.3.1. 140, 141 
Figure 5.3.1 
Macular regional map 
 
 
 
 
 
Table 5.3.4 
Macula anatomical regions Diameter of macula 
Fovea 1.55 mm Anatomical macula diameter 5.5-6 mm 
Foveal avascular zone 0.5 to 0.6 mm 
Foveala 0.35 mm Clinical macula diameter (Fovea) 1.5 mm 
Umbo 0.15 mm 
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The normal values of macular thickness and macular volume are listed in Tables 5.3.5. Normally, the 
thinnest part of macula is the central fovea area and the thickest part is within 3 mm diameter from the 
central macula to peripheral macula and then there is a further decreasing of thickness toward 
peripheral macula. The temporal part of macula is thinner than nasal part. 142, 143, 144, 145 
 
Table 5.3.5 
Normal macular thickness Normal macular volume by OCT 
Region Mean +/- SD Total macular volume 3.04 +/- 0.14 mm3 
Fovea (500 μm radius) 212±20 Central subfield volume 0.2122 +/- 0.017 mm3 
Center  
Automatically determined  
Manually determined  
 
182 ±23 
170 ± 18 
 
Inner ring (1,5 mm 
radius) 
Superior 
Inferior 
Temporal 
Nasal 
 
 
255 ± 17 
260 ±15 
251 ±13 
267 ± 16 
 
Inner ring (3 mm radius) 
Superior 
Inferior 
Temporal 
Nasal 
 
 
239 ± 16 
210 ± 13 
210 ± 14 
246 ± 14 
 
Overall, the mean CSF volume is 0.2122 +/- 0.017 mm3. Mean total volume (including all 
subfields) is 3.0382 +/- 0.1432 mm3. Among the ETDRS subfields (central fovea, inner 
macula and outer macula), the outer nasal quadrant had the maximum volume (0.3386 +/- 
0.016 mm3). The retinal volume did not show significant difference with age (P = 0.33), 
gender (P = 0.2) or race (P = 0.42). 145 
Normative values for total macular volume and volume in each subfield in otherwise healthy 
eyes were established using Spectralis SD-OCT. Based on these data, the present study 
proposes the guidelines for normal CSF volume to be 0.2122 mm3 for future studies using 
macular volume measurements with Spectralis SD-OCT. Macular volume data in various 
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conditions like macular edema and response to treatment will be of more importance than 
retinal thickness in clinical practice as well as a parameter for future clinical trials for 
treatment of such diseases.  
In this study, the central macular thickness and the macular volume have been monitored with 
the help of the OCT, Spectralis, Heidelberg Engineering GmbH. All the measurements have 
been performed using the same technique and the same OCT equipment. The central retinal 
thickness (CRT) value is referred to the central foveal area. 
 
5.4. Intravitreal injection procedure 
Intravitreal injection of 0.7 mg Dexamethasone implant is performed in aseptic condition. It 
has a special delivery system with a preload, single use applicator (Figure 5.4.1 and 5.4.2). 
Gloves, drape and eyelid speculum should be in sterile condition. The procedure is under 
local anesthesia. Prior to intravitreal injection, a prophylactic antibiotic local therapy is 
instilled. The periocular skin and the conjunctiva is disinfected and washed with 5% povidone 
iodine prior to the injection. 146 147 
 
Figure 5.4.1 
Procedure of 0.7 mg Dexamethasone implant injection 148 
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Figure 5.4.2 
Dexamethasone implant in visual field 149 
 
 
The administration of 0.7 mg Dexamethasone implant has the following steps: 
1) The long axis of the applicator is hold parallel to the limbus. 
2) The applicator is injected 1mm into the sclera at an oblique angle and hold parallel to the 
limbus. 
3) The applicator is then redirected towards the vitreous cavity. This will create as sclera 
tunnel. Then the needle enters into the vitreous cavity. 
4) The injection button is pressed slowly until a click.  
5) The applicator should be removed in the same direction as it has been entered.150 
 
5.5. Ozurdex® Implant 
Ozurdex® (Allergan, Irvine, CA, USA) 151 is a single use, slow release drug of 0.7 mg 
Dexamethasone approved by the European Medicines Agency (EMA) 152 (Figure 5.5.1). It is 
a biodegradable, tiny solid rod shape implant that is injected into vitreous of the eye and it has 
a solid polymer sustained release drug delivery system 153 and constituted of an intravitreal 
polyglactin (poly D,L-lactide-coglycolide) polymer matrix without a preservative. 
Dexamethasone itself has a white colored crystalline powder poorly soluble in water. 
Dexamethasone implant can dissolve natural over months as the copolymer matrix degrades 
to glycolic acid and lactic acid, which are metabolized to carbon dioxide and water 154 and 
does not need to be removed chirurgical. Dexamethasone implant has a minimal systemic 
absorption. 
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Figure 5.5.1 
0.7 mg Dexamethasone implant  
  
 
Pharmacologically, Dexamethasone is an inflammatory suppressor that acts as inhibitor of 
prostaglandin and pro-inflammatory cytokines (such as interleukins, tumor necrosis factor-α, 
interferon γ) which are associated with decreased edema, fibrin deposition, inflammatory cells 
migration and capillary leakage. Dexamethasone acts as a corticosteroid.  
The main indication of the 0.7 mg Dexamethasone implantation are non-infectious 
inflammatory eye conditions, a macula edema associated to a central or branch retinal vein 
occlusion and a macula edema due to diabetic retinopathy. 
The Ozurdex® implant has some advantages over orally cortisone therapy. There is a minimal 
systemic absorption and has not any significant interaction.  
The implant of 0.7 mg Dexamethasone has an action with an improvement of clinical findings 
up to 12 weeks then followed by a gradual declination. The overall efficacy is less than 24 
weeks.155  Other study has shown that in cases of macular edema associated with diabetes 
mellitus there is a functional and anatomical improvement with a duration of 4 months. 156 
A retrospective study of diabetic patients has showed that after repeated injection of 0,7mg 
Dexamethasone intravitreal implant there is no effect on HbA1c or renal function. But some 
transient changes of lipid profile (LDL cholesterol level) have been reported. 157 
It can be used in children (off label), during pregnancy (off label) or lactation. Repeated 
injections for long term use are safe.  
The main contraindications of the 0.7 mg Dexamethasone implant are any peri- or intra ocular 
infection, glaucoma patients with progressive disease, patients with associated cortisone 
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responding glaucoma, any condition of anatomical malformation of posterior lens capsule and 
in rare cases, patient with allergy to its ingredients.  
The main identified risks after 0.7 mg Dexamethasone implant are mentioned in table 5.5.1. 
Table 5.5.1 
Complication after 0,7 mg Dexamethasone implantation158 
Endophthalmitis (Infectious / non-infectious) Increased intraocular pressure 
Retinal detachment or retinal tear Posterior subcapsular cataract 
Implant dislocation Implant misplacement 
Increase risk of secondary eye infection due to 
bacteria, fungi or viruses 
Retinitis secondary to reactivation of latent 
viral infection 
Vitreous hemorrhage or detachment Rare systemic effects such as infection, 
healing impairment, hypertension 
 
5.6. Statistics 
The data of this study have been collected and analyzed initially with Microsoft® Office Excel 
365. The statistical analysis was performed and based on SPSS Statistics 25 (IBM, Armonk, 
NY, USA). Differences between two groups were determined by students-T-Test. In more 
than two groups an ANOVA with Bonferroni post hoc test was used. A p-value of <0.05 was 
regarded as statistically significant.  
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6. Results 
The study was conducted at the department of Ophthalmology of Ludwig Maximilians 
University in Munich, Germany and is a retrospective analysis of a total of 55 eyes of 44 
patients with an active non-infectious uveitis. Baseline patient characteristics are depicted in 
Table 6.1. 
Table 6.1 
Review and characteristics of patient and eyes treated with intravitreal 
Dexamethasone implant in noninfectious uveitis 
Patients 44 
Eyes 55 
Sex Male 15 (34%) Female 29 (66%) 
Age (years ± range) Male 60 [32-84] 
Female 59 [23-89] 
 
In total 157 injections were conducted.  Each eye has received 2 (at least) to 5 intravitreal 
injections of 0.7 mg Dexamethasone implant. Table 6.2 is to summarize the study patient drop 
and lost to follow up characteristics after the second injection. 
Table 6.2 
Number of Dexamethasone implants pro eye 
Total implants 157 Dexamethasone implants 
Implants pro eye 1 and 2 Dexamethasone implants 55 eyes 
 3 Dexamethasone implants 28 eyes 
4 Dexamethasone implants 11 eyes 
5 Dexamethasone implants 8 eyes 
 
The uvetic macula edema was the indicator parameter for the decision of intravitreal injection 
administration and was identified with OCT imaging. All patients underwent clinical and 
laboratory testing for exclusion of an infectious cause of uveitis (Table 6.3). As this study was 
conducted in a real life retrospective settings some patients have received additional topical 
and/or systemic medication, but did not receive any other intravitreal medication during this 
study (Table 6.4). 
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Table 6.3 
Summary of diseases according to anatomical SUN classification 159 
Anterior uveitis 17 eyes Iritis 2   eyes 
Iridocyclitis 15 eyes 
Intermediate uveitis 12 eyes Hyalitis 1   eye 
Posteriorcyclitis 11 eyes 
Posterior uveitis 20 eyes Papillitis / Papillophlebitis 2   eyes  
Choroiditits 1   eye 
Vasculitis 6   eyes 
Chorioretinitis 11 eyes 
Panuveitis 6 eyes   
Summary of diseases according to etiological classification 
Idiopathic 34 patients (44 eyes) HLA B27 (+) 1 patient 
Sarcoidosis 3 patients (4 eyes) Raynaud’s syndrome 1 patient 
Behcet’s disease 2 patients Psoriasis 1 patient 
B cell lymphoma 1 patient Birdshot 1 patient 
 
 
 
 
Table 6.4 
Therapies prior to Dexamethasone implant 
Topical Periocular steroids 33 Pt (40 eyes) 
 Intravitreal anti-VEGF 4 Pt (4 eyes) 
Therapies prior to and during time of Dexamethasone implant 
Local Steroids 30 patients (32 eyes) 
Anti-inflammatory [NSAID] 3 patients 
Systemic Steroids 27 patients 
 Acetazolamide (Diamox) 21 patients 
 Immunosuppressants 
> Methotrexate 
> Ciclosporin 
> Adalimumab  
> Azathrioprine 
> Mycophenolate  
> Interferon α2 
> Chemotherapy (Carboplatin) 
(25 patients)  
7 patients 
6 patients 
4 patients  
3 patients 
3 patients 
1 patient 
1 patient 
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Visual acuity, central macular thickness and macular volume were the primary parameters 
that have been studied and monitored. Additionally, intraocular pressure was measured as 
secondary parameter. The response to the Dexamethasone implant was measured by change in 
all parameters during follow ups of each injection of 0.7mg Dexamethasone implant.  
The monitoring and analysis of all clinical parameters was based on four follow ups intervals 
that have been set for an statistical analysis. Generally, the patient were seen at first, third and 
fifth month after the injection. The injection day was defined as the initial point of time of all 
intervals and it was counted as the starting point of each follow up of each injection. The time 
of each follow up after each injection is defined in Table 6.5.  
Table 6.5 
Overview of time intervals of follow ups after each Dexamethasone implant injection 
Day of injection Visit: V 1 
4 weeks follow up after the injection ± 1 week Visit: V 2 
3 months follow up after the injection ± 2 weeks Visit: V 3 
5 months follow up after the injection ± 1 months Visit: V 4 
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6.1. Visual acuity 
The initial BCVA of all 55 eyes (V1.1), before any 0.7 mg Dexamethasone implant, had a 
mean ± standard deviation (SD) value of 0.78 ± 0.43 logMAR. In the predefined interval of 
four weeks and after the first 0.7 mg Dexamethasone implantation (V1.2), there was a 
statistically significant improvement to 0.55 ± 0.42 logMAR. A mild visual deterioration to 
0.63 ± 0.47 logMAR has observed at the three months follow up (V1.3). By the last follow up 
at five months (V1.4) after 0.7 mg Dexamethasone injection, BCVA showed a further 
worsening to 0.73 ± 0.42 logMAR. 
In all 55 eyes, a second 0.7 mg Dexamethasone implant was inserted. The clinical response 
was similar to the first 0.7 mg Dexamethasone implant. The BCVA at the time of the second 
0.7 mg Dexamethasone implant (V2.1) had a mean value of 0.80 ± 0.45 logMAR. Four weeks 
later (V2.2) the mean BCVA has an improvement to 0.59 ± 0.44 logMAR with a mild 
reduction of mean VA of 0.61 ± 0.47 logMAR after a post injection interval of three months 
(V2.3). Finally at the post injection interval of five months the mean VA was 0.75 ± 0.53 
logMAR which shows a significant BCVA deterioration.  
Similar results have seen in the 28 eyes that continue to receive the third 0.7 mg 
Dexamethasone implant. The initial mean BCVA at the time of third injection (V3.1) was 
0.83 ± 0.49 logMAR with a further melioration of mean BCVA to 0.66 ± 0.52 logMAR 1 
month after the third injection (V3.2). At the time of three months (V3.3) after the third 
injection shows again a similar mild worsening of mean BCVA of 0.70 ± 0.77 logMAR. The 
last predefined follow up of five months (V 3.4), has showed again a reduction of mean VA at 
level of 0.85 ± 0.63 logMAR. 
Mean BCVA of the fourth and fifth injection showed similar results, however with a lower 
statistical significance than the first three injections because of the small number of cases. 
11 eyes have received a fourth intravitreal 0.7 mg Dexamethasone implant. The first 
measurement of mean BCVA at the day of injection (V4.1) was 0.72 ± 0.76 logMAR. A 
further statistical improvement of mean BCVA to 0.54 ± 0.40 logMAR was seen at the time 
of one month (V4.2). 0.80 ± 0.9 logMAR was the mean BCVA in period of three months after 
fourth injection (V4.3). Five months follow up (V4.4) shows again a worsening of mean VA 
to 0.70 ± 0.38 logMAR. 
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The last VA measurements have been monitored in eight (8) eyes after the fifth injection of 
0.7 mg Dexamethasone implant. The first time point of injection day (V5.1) had a mean 
BCVA of 0.87 ± 0.97 logMAR. There again was an improvement of mean BCVA to 0.78 ± 
1.1 logMAR in one month follow up (V 5.2). At the follow up of three months (V 5.3) was 
seen an improvement of mean BCVA (in comparison to other four0.7 mg Dexamethasone 
implants, probably due to insufficient data and reduced number of cases) to 0.28 ± 0.16 
logMAR. The last predefined interval of five months (V 5.4), has showed again a significant 
decrease of mean BCVA to 0.60 ± 0.46 logMAR (Diagram 6.1.1). 
 
 
Diagram 6.1.1 
VA mean and SD (logMAR / months) of all injection during follow ups 
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Diagram 6.1.2 represents the percentage of those cases that during follow up of the first three 
injections had an improvement of less than -0.3 logMAR. During the fourth and fifth 
injections were insufficient cases to review an accurate result.  
The percent of cases that had a BCVA difference of < - 0.3 logMAR between the day of 
injection and four week follow interval during first three injections were 34 % (first injection), 
38.6 % (second injection) and 33.3% (third injection). This difference of logMAR during the 
three month follow up were observed in 31 % (first injection), 28.9 % (second injection) and 
20.8 % (third injection) cases. During the last follow up at month 5 it was 20.8 %, 20.4 % and 
14.2 % respectively.   
 
 
Diagram 6.1.2 
% of cases that had an VA < Δ - 0.3 logMAR during each follow up of first three 
injections 
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6.2. Optical coherence tomography 
Central retinal thickness (diagram 6.2.1 and figure 6.2.1) and macular volume (diagram 6.2.2 
and figure 6.2.2) were followed up as the main anatomical study parameter for 
pharmacological response.  
After the first injection there was a statistically significant decrease in central retinal thickness 
from 540 mm ± 189 mm to 287 mm ± 107 mm (p<0.001) and macular volume from 10.6 mm3 
± 2.1 mm3 to 9.22 mm3 ± 1.2 mm3 (p=0.002) after 4 weeks of follow up. From baseline to 
three month this difference was still significant (p<0.001 for CRT and p=0.002 for MV). 
After five month the Dexamethasone implant did not exhibit any statistically significant effect 
on central retinal thickness and macular volume anymore (p=0.09 and p=0.82 respectively).  
The same pattern was observed for the second injection with a statistical significant effect at 
the time of 4 weeks (p<0.001 for CRT and p<0.001 for MV) and 3 months (p<0.001 for CRT 
and p=0.025 for MV) but the effect is diminished after five months (p=0.45 for CRT and 
p=0.93 for MV).  
In detail, the point time of V2.1 referred to the time of second 0.7 mg Dexamethasone 
implant, the CRT and MV measurement at this point was recorded as 507 mm ± 195 mm and 
10.7 mm3 ± 1.7 mm3. At four weeks (±) follow up (V2.2) a notable improvement to 280 mm 
± 137 mm and 9.2 mm3 ± 1.2 mm3 was seen. At the three months (± 2 weeks) control (V2.3), 
CRT and MV has been recorded as 318 mm ± 91.5 mm and 9.7 mm3 ± 1.1 mm3. The final 
follow up of CRT and MV values of second injection of 0,7 mg Dexamethasone implant 
(V2.4) were 446 mm ± 168 mm and 10.2 mm3 ± 1.7mm3and it had a similar worsening of 
OCT values as during the last follow up (V1.4) of the first injection of 0,7 mg Dexamethasone 
implant. 
Also after the third injection a statistically significant improvement of CRT and MV was seen 
(p=0.001 for CRT and p=0.044 for MV at the time of first follow up). Whereas the findings of 
the third and fifth month follow ups showed a reduction of effectiveness with p values of p= 
0.031 (CRT) / p=0.39(MV) and p=0.92 (CRT) / p=1.0 (MV) respectively.  
The CRT and MV values at the time of the third injection of 0.7 mg Dexamethasone implant 
(V3.1) were 476 mm ± 181 mm and 10.3 mm3 ± 2.4 mm3. The next time point V3.2 revealed 
measurements of 281 mm ± 86.1 and 8.8 mm3 ± 1.2 mm3, respectively, which demonstrated 
again an improvement of OCT values. V3.3 reported again and mild increase of CRT and MV 
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values to 328 mm +/- 104 mm and 9.3 mm3 ± 1.2 mm3. The last follow up V3.4 showed an 
obvious worsening of CRT and MV values with 549 mm ± 239 mm and 10mm3 ± 1.5 mm3.  
After the fourth and fifth 0.7 mg Dexamethasone implant similar results of mean and SD 
values of CRT and MV were recorded, but had lower accuracy as the first three injections due 
to lower number of clinical cases.  
The CRT and MV measurement of V4.1 after the fourth 0.7 mg Dexamethasone injection was 
recorded as 568 mm ± 257 mm and 10mm3 ± 1.8 mm3. A repeated improvement of mean 
CRT and MV was seen four weeks (± 1 week) after (V4.2) with mean and SD values of 253 
mm ± 64 and 8.5 mm3 ± 1.6 mm3. The V4.3 follow up showed a mild worsening of mean and 
SD CRT and MV to 341 mm ± 95 mm and 8.9 mm3 ± 1.5mm3. The final follow up of fourth 
injection of 0.7 mg Dexamethasone implant again demonstrated worsened measurements as 
high as 493 mm ± 156 mm and 10.3 mm3 ± 2.1 mm3, respectively. 
The measurement at the fifth 0.7 mg Dexamethasone injection were recorded in 8 eyes. The 
mean and SD results of CRT and MV at time point V5.1 was 547 mm ± 180 mm and 10.4 
mm3 ± 3.1 mm3. The V5.2 mean and SD values appeared again better as 325 mm ± 186 mm 
and 9.4 mm3 ± 2.5mm3 with a mild worsening at the point of V5.3 with values of 412 mm ± 
178 mm and 10.2 mm3 ± 1.3mm3. Lastly the mean and SD of CRT worsened again as 498 
mm ± 171 mm with a change of MV mean and SD values to 9.6 mm3 ± 0.4 mm3. 
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Figure 6.2.1 
All OCT-CRT follow ups during an injection of Dexamethasone implant 
Date of injection Follow up I (4 weeks +/- 1 week) 
  
Follow up II (3 months +/- 2 weeks) Follow up III (5 months +/- 1 month) 
  
 
Diagram 6.2.1 
CRT mean and SD (microns/months) of all injection during follow ups 
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Figure 6.2.2 
All OCT-MV follow ups during an injection of Dexamethasone implant 
Date of injection 
 
Follow up I (4 weeks +/- 1 week) 
 
Follow up II (3 months +/- 2 weeks) 
 
Follow up III (5 months +/- 1 month) 
 
46 
 
Diagram 6.2.2 
MV mean and SD (mm3/months) of all injection during follow ups 
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6.3. Intraocular pressure  
The intraocular pressure (IOP) in this study was monitored as a secondary parameter. In our 
cohort there was limited information about any possible additional local or systemic anti-
glaucomatous prescription which might have been prescribed in the outpatient setting, in 
between the predefined follow up intervals that take place at our department. This lack of 
detailed information impedes interpretation of IOP values. 
The mean and standard deviation of all five injections is summarized in diagram 6.3.1. 
Diagram 6.3.1 
Mean values (mmHg) and standard deviation of IOP during 5 Dexamethasone implants 
 
 
After injections a major IOP increase was observed in the fourth week of follow-up with a 
slow decline at the next time points. Since the standard deviation of IOP-measurements varies 
widely between individuals it is also important to analyze the percentage of eyes that showed 
an increase of 10 mmHg of more at different time points. 
After injection 1 at the post injection time of four weeks an IOP elevation of more than 10 
mmHg was observed in 8.6 % of the cases. The second follow up at month three after 
injection showed that in 4.5 % of the cases the IOP increased by more than 10 mmHg. After 
five months of follow up 4.3% of cases showed an IOP elevation of more than 10mmHg.  
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The clinical results during the second injection seemed to be similar as during the first 
injection. 12.1 % of cases had an IOP elevation more than 10 mmHg at four weeks interval 
after the second injection. Later, at time point of three months has observed an IOP 
improvement and only 5.7 % had an IOP increase over 10 mmHg. Finally at the time of five 
months the cases with IOP >10mmHg were reduced to 2.3 %.   
During third injection and at the time of four weeks follow there was no case with IOP 
elevation over 10mmHg, this is a comparable result to the first two injections and is ascribed 
to intensified usage of anti-glaucomatous medications. At three months interval after third 
injection an IOP increase of more than 10 mmHg was seen in 4.3 % cases. This was similar to 
the increase during the first two injections. Lastly, there were 10.5 % of cases with elevation 
of IOP over 10 mmHg after a post injection follow up time of five month. (Diagram 6.3.2 and 
Table 6.3.1). 
Diagram 6.3.2 
% of cases that had an IOP elevation < 10mmHg during each follow up of all injections 
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Table 6.3.1 
% of cases with IOP elevation > 10 mmHg after each Dexamethasone implant  
during all follow ups of the first three injections 
IOP V1.2 IOP V1.3 IOP V1.4 
8.6 % 4.5 % 4.3 % 
IOP V2.2 IOP V2.3 IOP V2.4 
12.1 % 5.7 % 2.3 % 
IOP V3.2 IOP V3.3 IOP V3.4 
0 % 4.3 % 10.5 % 
 
During fourth and fifth injections were not enough accurate measurable values due to least 
cases. 
The percent of the cases that had an elevation of IOP value > 10mmHg from time of first 
injection to all follow ups and even the time of each re-injection is listed in Table 6.3.2. 
Table 6.3.2 
% of cases with IOP elevation > 10 mmHg from day of first Dexamethasone implant to 
all follow ups and time of re-injections 
IOP 
V1.2 
IOP 
V1.3 
IOP 
V1.4 
IOP 
V2.1 
IOP 
V2.2 
IOP 
V2.3 
IOP 
V2.4 
IOP 
V3.1 
IOP 
V3.2 
IOP 
V3.3 
IOP 
V3.4 
8.6 % 4.5 % 4.3 % 1.9% 6.9% 5.2% 4.4% 3.5% 0% 8.6% 10.5% 
 
A general evaluation of our measurements showed a similar result during all five injection of 
0.7 mg Dexamethasone implant. The maximal mean value IOP elevation difference was 0.7 
mmHg to 2.7 mmHg at the time point of four weeks (± 1 week) after the injection. 0.6 mmHg 
to 1.3 mmHg was the maximal mean value IOP elevation difference at the time point of three 
months (± 4 weeks). Finally the mean value difference at the time point of V4, five months (± 
1 month), was between - 0.1 mmHg to 1 mmHg, this difference is not an important IOP 
change. It is likely due to lack of Dexamethasone action.160  
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6.4. Cataract surgery and other associated factors 
In addition to the main parameters of this study (VA, central retinal thickness, macular 
volume and IOP), the lens status was recorded since corticosteroids as well as inflammation 
cause cataract. Prior to the initiation of 0.7 Dexamethasone therapy, 28 eyes were 
pseudophakic already. Four (4) eyes were already aphakic prior the first injection of 0.7 mg 
Dexamethasone implant and only one (1) has to proceed to a secondary IOL implantation 
during the follow ups period. In 23 eyes mild to advanced cataract was recorded and 15 of 
these 23 eyes underwent cataract surgery during the study period. Only 8 eyes (34.8 %) have 
kept the physiological lens during this study (Table 6.4.1). The correlation between cataract 
operation and number of injection of 0.7 mg Dexamethasone implant is listed in table 6.4.2. 
Table 6.4.1 
Lens status prior Dexamethasone treatment 
Aphakia 4 
Phakia 23 
Pseudophakia 28 
Cataract operation or secondary IOL implantation during Dexamethasone treatment 
Cataract operation during IVOMs 15 
IOL implantation in aphakic eyes during IVOMs 1 
 
Table 6.4.2 
Cataract operation in correlation to number of injection 
IVOM 1 7    Eyes underwent to cataract operation 
IVOM 2 6    Eyes underwent to cataract operation 
IVOM 3 1    Eyes underwent to cataract operation 
IVOM 4 1    Eye underwent to cataract operation 
 
The cataract formation of the 15 eyes and subsequent cataract operation with implantation of 
an artificial intraocular lens (IOL) was due to steroid as side effect. Other important factor of 
secondary cataract formation was the inflammation.   
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7. Discussion 
In this retrospective study, we have examined the clinical long term outcomes of patients with 
non-infectious uveitis and cystoids macular edema after repeated injections of 0.7 mg 
Dexamethasone implant. Our clinical results were the following: 
(1) BCVA was always improved to a maximum at 4 weeks (± 1 week) after every injection of 
0.7 mg Dexamethasone implant and slowly deteriorated to the level of pre injection time 
point. This BCVA improvement occurred regularly after each injection, independently of 
injection number except during the fifth injection, probably due to the small number of cases. 
A remarkable point was that BCVA has the best value at pre injection time point of fourth 
injection if we compared to the first three initial pre injection time points.  
(2) Our result shows that the central macular retinal thickness was minimal at 4 (± 1 week) 
after each intravitreal injection of 0.7 mg Dexamethasone implant with a slow worsening 
during the following months and with mild central retinal thickness increasement at the time 
point of 3 months (± 2 weeks). Finally at the time point of 5 months the macular thickness 
was identical to the pre injection time point. This effect was seen after each injection of 0.7 
mg Dexamethasone implant independently to injection number and it had similar result during 
all of five injections. 
(3) During the second and the third injection, the initial central retinal thickness at the pre 
injection time point was gradually reduced in comparison to the initial central retinal 
thickness of first injection at pre injection time point. This effect was not seen during the 
fourth and fifth pre injection time point, but we have seen a mild elevation of initial central 
retinal thickness in comparison to the second and third pre injection central macular thickness. 
This is possible due to chronic inflammatory process with subsequent post inflammatory 
changes of anatomical structure of macula or due to reduced cases during the fourth and fifth 
injection.   
(4) The result of intraocular pressure have shown that during the first and second injection 
there was an elevation of intraocular pressure at the time point of 4 (± 1 week) weeks and a 
mild improvement with a reduction of IOP at the time point of 3 (± 2 week) months. Finally 
the IOP values at the time point of 5 (± 1 months) months returned to the pre injection time. 
This noticeable IOP change at time point 4 (± 1 week) weeks, was not seen during the third 
injection, most likely due to prescribed anti-glaucomatous therapy after IOP complication 
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during the first two injection. During the fourth injection there was again an IOP elevation. 
We speculate that this depends on the additional use of anti-glaucomatous drugs.   
(5) The lens opacity and a possible subsequent cataract operation during injections period has 
been studied and monitored as secondary finding. This analysis has showed a remarkable 
result. 65,2 % of 23 eyes have proceeded to an early cataract operation with implantation of 
an artificial IOL during the time of our study after repeated injections of 0.7 mg 
Dexamethasone implant and only 34.8 % have kept the physiological lens during this time. 
The lens opacity during our study was correlated with BCVA values but it was independently 
to the improvement of the other clinical condition such as of central retinal thickness and 
macular volume.  
(6) The BCVA was a functional parameter in this study and could be related to central 
macular thickness as an anatomical factor. In addition to central retinal thickness other 
secondary factors such as early cataract (in phakic eyes), secondary cataract, cataract surgery, 
epiretinal gliosis, anatomical changes from chronic inflammatory process and chronic 
elevation of intraocular pressure with secondary glaucoma (due to cortisone respond or due to 
chronic inflammation) contribute to the final clinical result of visual acuity. 
Several studies have focused on different treatments of non-infectious uveitis with cystoids 
macular edema. The efficacy, safety side effect and clinical response of 0.7 mg 
Dexamethasone implant has been discussed in several reports with different points of view.   
The study Intravitreal Dexamethasone implant for the treatment of macular edema in chronic 
non-infectious disease has shown that the Dexamethasone implant is an effective treatment 
additional to systemic therapy with steroids or immunomodulator and require a further 
investigation to set the Dexamethasone implant as single therapy for chronic uveitic macular 
treatment. This study had monitored two main parameters CRT and BCVA. There was an 
improvement of CRT in 91.4% of cases and the BCVA was better in 80% of all eyes three 
months after the 0.7 mg Dexamethasone implantation. Additionally there was similar clinical 
improvement in CRT and BCVA after repeated injections of 0.7 mg Dexamethasone 
implantation.  The treatment success was reported to be between third and sixth month after 
the injection. 161 
In our study, during the first injection there was a significant improvement of CRT in 98% 
cases during the follow up time of four weeks. The BCVA increased in 86% of cases during 
the time point of four weeks after the first injection. Both studies have the same therapeutic 
53 
 
indication for macular edema in non-infectious uveitic eyes but all cases of our study have 
received a repeated injection in comparison to this study that a repeated injection was 
occurred in 28.5%. The repetition of implant at the same eye has shown similar effect in both 
studies with melioration of clinical findings.  
The CHROME study have tested the efficacy and safety of single or multiple intrvitreal 0.7 
mg Dexamethasone implant in cases with macular edema due to uveitis, vein thrombosis, 
diabetes mellitus. The parameters were BCVA, CRT, IOP and cataract surgery and have been 
monitored ≥ 3 months after injection. In the subgroup of uveitis patients the study had 
concluded that the 0.7 mg Dexamethasone implant as single or combined therapy resulted in 
anatomical and functional improvement in cases with chronic macular edema and of cases had 
a repeated second and third injection. All cases had a significant improvement of BCVA and a 
decrease of central retinal thickness. 22.7% of uveitic eyes had an IOP elevation to ≥ 10 
mmHg. 29.8% of eyes underwent to cataract surgery. 162 
In our study 65.2 % of eyes have proceeded to cataract operation. The difference to the 
CHROME-study is that in our study, the cases have received at least two up to five injections 
in comparison to 1 to 3 injections.   
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8. Summary 
The intravitreal 0.7 mg Dexamethasone implant (Ozurdex®) in eyes with non-infectious 
uveitis demonstrated a significant improvement in visual acuity and central retinal thickness 
with peak effect at four weeks after implantation. A further stabilization was observed until 
the third month but five months post implantation the efficacy was lost.  
Additionally, ocular side effect such as mild transient elevation of intraocular pressure and 
cataract formation was reported during this study. In both cases after a proper management 
with anti-glaucomatous drugs or cataract operation have shown an improvement of clinical 
findings and visual acuity.  
Thus, the 0.7 mg Dexamethasone implant can be used safely as standard therapy in cases of 
non-infectious uveitis with macular edema with a satisfactory result to controlling the disease 
in functional and anatomical point of view but requires repeated administration and tight 
control of side effects. 
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9. Zusammenfassung 
Das intravitreale 0.7 mg Dexamethasone Implantat (Ozurdex®) bei Augen mit nicht-
infektiöser Uveitis, zeigt eine deutliche Verbesserung des Visus und der zentralen 
Netzhaudicke, mit einer Maximalwirkung vier Wochen nach der Implantation. Eine weitere 
Stabilisierung wurde bis zum dritten Monat nach der Implantation festgestellt jedoch war fünf 
Monate nach der Implantation keine Wirksamkeit mehr sichtbar. 
Außerdem wurden während dieser Studie Nebenwirkungen, wie zum Beispiel eine leichte 
transiente Erhöhung des intraokulären Augendrucks und eine Kataraktformation festgestellt. 
In beiden Fällen war, nach geeigneter anti-glaukomatöser Therapie oder Katarakt-Operation, 
eine Verbesserung der klinischen Befunde und des Visus zu vermerken. 
Zusammenfassend kann das 0.7 mg Dexamethason-Implantat bei nicht-infektiöser Uveitis mit 
Makulaödem mit einem zufriedenstellenden Ergebnis zur Kontrolle der Erkrankung in 
funktioneller und anatomischer Hinsicht sicher als Standardtherapie eingesetzt werden. Es 
erfordert jedoch eine wiederholte Verabreichung und strenge Verlaufskontrollen, um 
mögliche Nebenwirkungen frühzeitig zu erkennen. 
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